

Haematologica
HAEMATOL/2017/168401
Version 4

A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Marek Trnny, Gregor Verhoef, Martin JS Dyer, Dina Ben Yehuda, Caterina Patti, Miguel Canales, Andrés Lopez, Farrukh T Awan, Paul G Montgomery, Andrea Janikova, Anna M Barbui, Kazimierz Sulek, Maria J Terol, John Radford, Anna Guidetti, Massimo Di Nicola, Laure Siraudin, Laurence Hatteville, Sandrine Schwab, Corina Oprea, and Alessandro M Gianni

Disclosures: MT reports grants and personal fees from Roche, Celgene, Janssen, and Amgen, outside this work. JAR reports grants from Sanofi and Takeda, and personal fees from Takeda (speaker engagements and advisory boards), Cell Medica (advisory board), Novartis (advisory board), and Seattle Genetics (speaker engagements), outside this work. FTA reports personal fees for advisory boards, unrelated to this work, from Boehringer Ingelheim, Novartis Oncology, and Gilead. LS reports personal fees from Lincoln (contractor for Sanofi), during the conduct of this study. LH is an employee of Sanofi. CO is an employee and a stockholder of Sanofi. GV, MJSD, DBY, CP, MC, AL, PGM, AJ, AMB, KS, MJT, AG, MDN, SS, and AMG declare no competing interests.

Contributions: MT, LS, LH, SS, CO, and AMG were responsible for the study design. Data on this study was collected by all authors. The study data was interpreted by all the authors and analyzed by LS, LH, SS, and CO. MT and AMG drafted the manuscript and GV, MJSD, DBY, CP, MC, AL, FTA, PGM, AJ, AMB, KS, MJT, JR, AG, MDN, LS, LH, SS, and CO all critically reviewed the manuscript. All authors gave final approval of the version to be published.